Intuitive Surgical's third-quarter results are likely to reflect solid performance in the company's Instruments & Accessories segment. Improving margins buoy optimism.
Strength in Analytical Instrument and Specialty Diagnostics segments is likely to have driven Thermo Fisher's third-quarter 2024 performance.
Myriad Genetics and Ultima Genomics to explore the latter's sequencing platform for advanced clinical tests in oncology and reproductive genomics.